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Abstract
Ischemic tolerance defines transient resistance to lethal ischemia gained by a prior sublethal noxious stimulus (i.e.,
preconditioning). This adaptive response is thought to be an evolutionarily conserved defense mechanism,
observed in a wide variety of species. Preconditioning confers ischemic tolerance if not in all, in most organ sys-
tems, including the heart, kidney, liver, and small intestine. Since the first landmark experimental demonstration of
ischemic tolerance in the gerbil brain in early 1990’s, basic scientific knowledge on the mechanisms of cerebral
ischemic tolerance increased substantially. Various noxious stimuli can precondition the brain, presumably through
a common mechanism, genomic reprogramming. Ischemic tolerance occurs in two temporally distinct windows.
Early tolerance can be achieved within minutes, but wanes also rapidly, within hours. Delayed tolerance develops
in hours and lasts for days. The main mechanism involved in early tolerance is adaptation of membrane receptors,
whereas gene activation with subsequent de novo protein synthesis dominates delayed tolerance. Ischemic precon-
ditioning is associated with robust cerebroprotection in animals. In humans, transient ischemic attacks may be the
clinical correlate of preconditioning leading to ischemic tolerance. Mimicking the mechanisms of this unique endo-
genous protection process is therefore a potential strategy for stroke prevention. Perhaps new remedies for stroke
are very close, right in our cells.
Review
Surviving a sublethal noxious insult may result in a
more powerful state against a following lethal insult,
referring to Nietszche; “What doesn’t kill you, makes
you stronger.” This phenomenon named as precondi-
tioning (PC) and tolerance has been shown to exist in
many organs, most extensively in the heart. The first in
vivo evidence of preconditioning and tolerance in brain
was provided in 1960’s [1,2], but almost three decades
passed without any interest from researchers on this
unique phenomenon, until Kitagawa et al. opened the
research era of cerebral ischemic tolerance (IT) [3].
The ability to withstand, respond to, and to cope with
ongoing stress is a fundamental property of all living
organisms [4]. The fate of the brain tissue after focal
cerebral ischemia is determined by the degree and dura-
tion of ischemia, and even without preconditioning,
resident brain cells naturally respond to brain ischemia
by mobilizing a host of defences and counter responses
to mitigate cell injury and death [5]. If the subthreshold
noxious stimulus is too mild or negligibly mild, it may
not induce any response, whereas if it is sufficient
enough, it may serve as a PC trigger, or if it is too
severe, over the threshold, may permanently injure tis-
sues. The hallmark of PC stimulus is not being injur-
ious. In the scenario of IT, PC stimulus primes the
brain for subsequent injurious ischemic injury. Danger
signal evoked in the brain by the stressing precondition-
ing stimulus induces complex endogenous protective
mechanisms resulting to a latent protective phenotype.
When the lethal ischemic insult is applied onto this
latent protective phenotype, a separate set of responses
are triggered that constitute ischemia-tolerant pheno-
type, which strikingly differs from the unprimed or
unpreconditioned brain’s phenotype (Figure 1). There-
fore, the outcome of the brain cells is shifted by PC
from death to survival. * Correspondence: aysan.durukan@hus.fi
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ebral IT were intensely studied, and although incom-
plete, a vast amount of knowledge has been
accumulated. The salient features of cerebral IT are pre-
sented in Table 1. There are two temporally distinct
windows of protection from ischemia afforded by PC.
Early protection, i.e., early IT, has been observed in rela-
tively fewer studies than those exposing late IT in the
brain. Exploring the functional relevance of these find-
ings has proved difficult, however.
In this review article, we first attempted to clarify the
IT nomenclature. Various triggers induce cerebral IT;
these are mentioned in a separate section discussing the
models for IT. This variety among preconditioning trig-
gers indicates that the downstream signaling pathways
converge on some common fundamental mechanisms
[5], major mechanisms are discussed briefly. A number
of tools serve for examination of the efficacy of PC,
chief methods are exampled. Lastly, we addressed the
challenging issues of IT to encourage further research.
I. Nomenclature
The nomenclature used in the studies addressing the IT
phenomenon is not entirely consistent. In this article, in
order to keep with consistency while defining the meth-
odology of the IT experiments and to provide ease for
reading, the following terms will be used according to
the definitions given:
PC
The stimulus or the method applied in an experiment
that triggers IT in the brain.
Ischemic preconditioning (IPC)
Method of PC by inducing either global or focal transi-
ent cerebral ischemia. When the PC stimulus is different
than ischemia, PC will be named according to the nat-
ure of the trigger (e.g., hypoxic-PC, anesthetic-PC, che-
mical-PC). In the literature, sublethal or priming
ischemia have been used as alternative terms to IPC.
For subsequent ischemic insult given after PC, the term
Figure 1 Outcomes in the different settings with middle cerebral artery occlusion (MCAO). In the absence of ischemic preconditioning
(IPC), MCAO induces a large infarction (ischemia-sensitive phenotype). IPC results early ischemic tolerance (IT) in minutes; if MCAO is applied
during this phase, mainly cortical areas are spared (early ischemia-tolerant phenotype). In hours, the brain regresses to its naïve state. Delayed
phase of IT occurs in days, when the latent cerebroprotective phenotype is complete, the brain is again ischemia-tolerant.
Table 1 Main futures of cerebral ischemic tolerance
General Preconditioning specific
￿ Robust cerebroprotection ￿ Two phased: early and delayed
￿ The interval between preconditioning and ischemia determines
the fate
￿ Early tolerance starts in minutes, delayed tolerance not usually before
24 h
￿ Ischemic tolerance is transient ￿ After early phase, but before delayed phase no tolerance is achieved
￿ Ischemic tolerance can be induced by a variety of stimuli ￿ Early phase is short-lasting, delayed phase longer, up to 1 week
￿ Transient ischemic attacks confer ischemic tolerance in humans ￿ Preconditioning preserves cortical/penumbral tissue in focal ischemia
models
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lethal, reference, or full ischemia). We will prefer to
name the subsequent ischemic event as final ischemia.
IT
Briefly, the protection from final ischemia provided by
prior PC refers to as IT. Depending on the media used
to study the phenomenon of IT, IT may refer to the
cell, tissue, or organ’s post-ischemic state wherein, due
to previous PC exposure, the response to ischemia is
different from one observed without previous PC. In
this article therefore, PC and IT define two different
(but related) entities and are not used interchangeably.
Ischemia-tolerant phenotype (Figure 1)
It is the consequence of both pre- and post-ischemic
protective responses induced by PC [5]; in other words,
it is the resulting phenotype from both PC and final
ischemia.
Latent cerebroprotective phenotype
It determines the status of the cell, tissue, or organ
exposed to PC that experiences changes triggered by
PC, and it occurs before the application of final ischemia
[5]. Hence, the latent cerebroprotective phenotype dif-
fers from the ischemia-tolerant phenotype by the lack of
exposure to final ischemia (Figure 1).
Cerebroprotection or protection
With the better understanding of the concept of neuro-
vascular unit (i.e., the contribution of glial and vascular
endothelial cells and their interactions with neurons in
physiological and pathological conditions), researchers’
attention shifted from neurons towards cerebrum.
Hence, instead of “neuroprotection”,w ep r e f e rt ou s e
“cerebroprotection”, which covers not only neurons but
all the cerebral cell populations experiencing IT. To
interpret IT afforded on single cell type (hippocampal
CA1 neurons in global ischemic models or type of cell
slice used in vitro study), the protective effect provided
by PC will be discussed as “protection”.
II. Two phases of IT
Preconditioning induces two phases of IT with different
temporal profiles and, to some extent, with different
mechanisms of protection: early and delayed IT (Figure
1); the latter plays the major role in the brain. Early IT
is a short-lasting protection induced within minutes of
exposure to PC and wanes within hours. In this process,
rapid changes in activity and posttranslational modifica-
tions of existing proteins are involved, whereas delayed
IT requires gene induction and de novo protein synth-
esis, that represent a long-term response through
genetic reprogramming [4]. If the final ischemia is
induced during the unprotected window, which exists
between early and late IT (usually 30 min-1 hour after
PC, lasting up to 24 hours), no tolerance occurs (Figure
1).
In the literature, early IT has been termed as the first
window of protection [8], rapid IT [5], immediate IT
[9], short-term protection [8], classical IT [10], or acute
IT [4]. We will prefer to use early IT [10]. Alternative
terms for delayed IT are: second window of protection
(a term widely used in heart IT studies), classical IT [5],
and late IT [11].
III. Models for IT
Study setups for investigating potential phenotypes
induced by PC are exampled in Figure 2. A summary of
the available rodent models of IT is included in the fol-
lowing link as Additional File 1.
Global-Global
Animal models of global cerebral ischemia are designed
to mimic cardiac arrest in humans. Global-global IT
models include different durations of transient global
ischemia as PC and final insult.
Four-vessel occlusion
Rat forebrain ischemia experiments necessitate the
occlusion of both posterior and anterior blood circula-
tion of the brain. Four-vesselo c c l u s i o nw a so r i g i n a l l y
described by Pulsinelli et al. [12] as a two-stage proce-
dure wherein first both vertebral arteries are perma-
nently closed and the following day, both carotid
arteries are occluded. The model has been modified
later by the same authors [13] and others [14]. In rats,
delayed IT was provided by 3 [15] and 5 min [16] of
four-vessel occlusion to 6 to 20 min of final global
ischemia [15-17]. Appropriate durations of PC and the
interval between PC and finali s c h e m i ai nt h i ss c e n a r i o
have been studied by monitoring postischemic Hsp72
protein expression as a marker of IT [18]. Neither 3,
nor 8 min of IPC induced sufficient synthesis of Hsp72.
Once PC was fixed to 4 to 5 min, the minimum 2 days
of interval was required between PC and final ischemia.
Two-vessel occlusion and hypotension
This model, originally described by Smith et al. [19] in
the rat, includes bilateral carotid artery occlusion and
systemic hypotension induced by withdrawal of arterial
blood. Compared to four-vessel occlusion, it is less inva-
sive and more reproducible, as the depth of ischemia
depends on hypotension, rather than on surgical
attenuation of collateral perfusion [20]. PC by 2 to 3
min of two-vessel occlusion induces delayed IT in rats
to 5 to 10 min of final global ischemia [21-23]. Early IT
was also achieved in this model [24].
Durukan and Tatlisumak Experimental & Translational Stroke Medicine 2010, 2:2
http://www.etsmjournal.com/content/2/1/2
Page 3 of 18Two-vessel occlusion in gerbils
The gerbil mostly lacks a functioning circle of Willis
[25], a short period of bilateral occlusion of carotid
arteries (3-5 min) therefore leads to severe damage in
CA1 pyramidal neurons [26,27]. First introduced by
Kitagawa et al. [3], PC by single 2-min bilateral carotid
occlusion (or two times), 1 to 7 days before final ische-
mia in the gerbil brain has been a well-standardized
method to study IT [28-30]. A disadvantage of the gerbil
two-vessel occlusion model is that the severity of fore-
b r a i ni s c h e m i ai sh i g h l yi n f luenced by the anatomical
variations, which are not seldom [31]. Here, we should
note that thresholds for severity (i.e., duration of the
bilateral carotid occlusion), differentiating the outcome
as either PC or final insult, are in a narrow scale. To
overcome this issue and ensure a better control over the
ischemia severity, Abe and colleagues [7] provided a
useful modification of the model. By monitoring depo-
larizations, they largely eliminated the variability of the
ischemia and IT. This approach later was introduced in
a rat global-global IT model using four-vessel occlusion
[32].
Two-vessel occlusion in mice
This method, borrowed from its equivalent in gerbils,
may induce reproducible striatal injury in mice [33]. For
a delayed IT paradigm, Wu et al. applied 6 min of two-
vessel occlusion as PC and 18 min of bilateral carotid
artery occlusion as final ischemia in C57BL/6 mice [34].
As this strain is a common subject of transgenic tech-
nology, the model proved useful for investigating the
molecular mechanisms of IT in gene-modified mice. In
Figure 2 Exemplary protocol of a series of ischemic tolerance (IT) experiments. Preconditioning ischemia (IPC) lasts 5 min, final ischemia
10 min. Cross indicates the end of the study where the brains are collected for ex vivo evaluations. Set I experiments evaluate early IT: final
ischemia is applied 30 min after IPC (upper row), early ischemia-tolerant phenotype is tested by collecting the brains 25 min after PC, and in the
control experiment, final ischemia is induced without prior IPC (lower row). In Set II experiments, delayed IT (upper row, final ischemia induction
24 h after the PC) and delayed ischemia-tolerant phenotype (middle row, brains are collected 24 h after PC) are investigated, along with a
control experiment (lower row). Set III experiments address long-lasting effects of delayed-IT, with a follow-up lasting several weeks after final
ischemia.
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period (20 min) has induced delayed IT [35].
Focal-Focal
Transient focal-permanent focal
Transient occlusion of the middle cerebral artery (MCA)
by intraluminal insertion of a nylon monofilament, which
was originally described by Koizumi et al. [36] and modi-
fied by others [37], is the most common model to induce
focal cerebral ischemia in rats [38-41] and also available
in mice [42-45]. This method was introduced first time
in a rat IT experiment, applying 10 min of transient
MCA occlusion (tMCAO) as the PC stimulus and perma-
nent MCAO as the final ischemia [46]. Authors evaluated
IT phenomenon with several reperfusion periods
between IPC and final ischemia and showed that
ischemic lesions involving both cortex and basal ganglia
could be reduced when final ischemia was applied 1, 2,
and 7 days after PC, but not 2, 6, and 12 hours or 14 and
21 days after PC. This model was applied successfully by
others to obtain delayed IT [47,48]. Repeated brief transi-
ent ischemia regimen was also proved as a precondition-
ing paradigm inducing early IT in mice subjected to
permanent focal ischemia [49,50].
Transient focal-transient focal
One [51,52] or 3 times of 10 min transient focal cerebral
ischemia protects from subsequent 120 min of tMCAO
in rats [53-55]. Shorter durations (2 and 3 min) of
tMCAO were severe enough to induce delayed IT, but
did not provide early IT to transient ischemia [56,57].
Transient focal-focal IT paradigm induced IT also in
mice and spontaneously hypertensive rats [58,59]. A
recent mouse model of delayed-IT involves 2 periods of
5-min tMCAO as the PC method, against 90-min
tMCAO applied in 3 days, but not in 2 or 4 days [6].
Global-Focal
Brief global ischemia can protect from both subsequent
transient and permanent focal ischemia [60,61].
Focal-Global
Brief unilateral occlusion of the MCA induced significant
protection from global ischemia in both gerbils [62] and
rats [63]. Interestingly, transient (20 min) occlusion of
the distal MCA protected only ipsilateral parietal cortex
of the rat from global ischemia (10 min) [64].
Cross-Tolerance
Cross-tolerance is tolerance to ischemia provided by
miscellaneous noxious stimuli, rather than ischemia.
These differ greatly in nature, nevertheless, because of a
common reason (most likely by inducing genetic repro-
gramming), all furnish IT. Examples of cross-tolerance
in the scenario of transient focal cerebral ischemia are
provided in Table 2.
Hypoxia
Exposure of neonatal rats to 8% oxygen for 3 hours pro-
vides cerebroprotection from a combined hypoxia/ische-
mia model [65] and also from both transient and
permanent focal cerebral ischemia [66,67]. Varying
hypoxia durations (1, 3, or 6 hours) result in similar
extent of protection, but when the interval between
hypoxia and final ischemia exceeds 72 hours, IT
abolishes [67].
Hyperbaric oxygen
Hyperbaric oxygen was found protective from subse-
quent global ischemia in gerb i l s[ 6 8 ]a n df r o mp e r m a -
nent focal ischemia in SV129 mice [69], whereas it did
not induce IT to transient focal ischemia in these mice
[69]. Rats were protected from transient ischemia by
hyperbaric oxygen PC, but they were not protected from
permanent ischemia [70]. Repeated hyperbaric oxygen
application seems to induce IT to global ischemia in the
rat brain for a shorter period than 72 h [71].
Hyperthermia
In rodent experiments, indirect brain temperature can
be measured with a probe placed under the temporal
muscle and can be maintained at a desired level by hea-
ters allowing feedback adjustments. Chopp et al. first
time observed the PC effect of hyperthermia in rats sub-
jected to global ischemia [72]. Hyperthermia was pro-
tected as well neonatal rats from hypoxia/ischemia [73].
Hypothermia
The hypothermic-PC has been described in a rat model
of focal transient ischemia [74] and later was studied
systematically in order to define the optimal depth,
duration, and the method of application (global versus
focal hypothermia) [75]. The extent of protection was
dependent on the depth and duration of the hypother-
mia, focal cooling being as effective as systemic cooling.
Although the deeper the hypothermia, the bigger the IT
response was, mild to moderate levels of hypothermia,
which are safe in humans [76], were efficient as well.
This may encourage clinicians to test hypothermia as a
preconditioning strategy, for instance before vascular
surgical interventions with high risk of ischemic events.
Spreading depression
Leão’s spreading depression is a generalized and stereo-
typed response of the cerebral cortex to a variety of
noxious stimuli and is characterized by a slowly moving,
transient, and reversible depression of cortical electrical
activity that spreads like ripples in a pond; these waves,
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tex of the ipsilateral brain hemisphere with a speed of 2
to 5 mm per minute [77]. Topical application of high
concentration of potassium chloride onto the cortex
induces spreading depression that repetitively extends
from the sites of increased extracellular potassium con-
centration with a frequency of approximately 7/100 min
[78]. This method has been an effective PC trigger in
both global [79] and focal ischemia models in rats
[80-82]. IT induced by spreading depression seems to
develop in a delayed manner (in 3-6 days) [83,84] and
was shown to persist up to 15 days [85].
Remote IPC
Limb ischemia by bilateral femoral artery occlusion pro-
tects rat from either global ischemia [86] or transient
focal ischemia [87]. It can be applied as well repeatedly
(5-10 min for 3 times, with 10 minutes intervals in
between). This PC approach was successfully tested in
humans to induce IT in the heart [88]. Mesenteric
artery occlusion for 15 min was protective against bilat-
eral carotid occlusion in mice [89].
3-nitropropionic acid (3-NPA)
This is the most extensively studied chemical PC agent,
which inhibits oxidative phosphorylation. Intraperitoneal
administration of 3-NPA, 72 hours before transient focal
ischemia, is a well-established PC trigger for rats
[90-93]. Regarding the efficacy of 3-NPA as a PC trigger,
some contradictory results came from gerbil models of
global ischemia [94-96], but these may be related to the
doses used [97].
Lipopolysaccharide (LPS)
LPS is a cell-wall component of gram-negative bacteria. A
small dose provides IT in the brain. This has been proven
in a number of experiments including both transient
[98,99] and permanent [100,101] focal ischemia models in
rats, as well as in a mouse model of transient focal ische-
mia [102]. With higher doses no PC effect occurs [98].
Anesthetic-PC
Potential protective effects of anesthetics from an
ischemic insult have been known for long time [2] and
were well-studied in experimental stroke models as a
cerebroprotective strategy (for reviews see [103-105]).
Among anesthetics, isoflurane is the most commonly
used volatile anesthetic in IT experiments. Different
concentrations (0.5-4%) and varying durations (15 min-3
hours) of isoflurane inhalation have been efficient to
induce both early [106,107] and delayed IT in vivo
[108,109] and in vitro models [110,111]. Among other
anesthetics, xenon [112], halothane [113], and sevoflur-
ane [114] may also induce IT in animal models. Aneste-
tic-PC has been proven a promising PC method for
heart in humans [115].
Pharmacological PC
Several clinically available drugs, including estrogen
[116], erythromycin [117,118], and erythropoietin
Table 2 Amount of histological protection afforded by preconditioning in selected studies of focal cerebral ischemia
Protection* (%) Follow-up** Ref.
Focal-focal, in rats
15 min MCAO - 72 h later pMCAO 41 24 h [47]
10 min MCAO - 72 h later 60 min tMCAO 44 7 d [59]
3 min tMCAO - 72 h later 60 min tMCAO 35 24 h [57]
Focal-focal, in mice
3 × 5 min tMCAO - 30 min later pMCAO 23 24 h [50]
3 × 5 min tMCAO - 30 min later 60 min tMCAO 32 24 h [49]
15 min MCAO - 72 h later 45 min tMCAO 70 24 h [58]
LPS
LPS 0.5 mg/kg - 72 h later 60 min tMCAO in rats 35 24 h [98]
Hypoxia
11% oxygen for 2 h - 48 h later 90 min tMCAO in mice 46-64 24 h [66]
Anestesia
Isoflurane 1.4% for 3 h - 0, 12, and 24 h later pMCAO in rats 31-35 4 d [113]
Halothane 1.2% for 3 h - 24 h later pMCAO in rats 35 4 d [113]
Spreading depression
KCl application - 4 days later 120 min tMCAO in rats 43 4 d [191]
Hyperbaric oxygen
100% oxygen for 1 h, 5 days-24 h later pMCAO in mice 27 24 h [69]
Ref, references; *Reduction in the ischemic damage due to preconditioning; **Time-point of the histopathological analysis after final ischemia
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Acetylsalicylic acid [121] and kanamycin [122] were
effective as PC agents in vitro.
Other models for IT
Repeated electroacupuncture [123,124], electrical stimu-
lation of cerebellar fastigial nucleus [125], and dietary
restriction [126] protected rats from subsequent transi-
ent focal ischemia. In global ischemia rat models, repeti-
tive transcranial magnetic stimulation [127],
electroconvulsive shock [128], kainite-induced epileptic
seizures [129], and sleep deprivation [130] all have
served as PC stimuli.
In vitro models
Neuronal cell culture systems provide an ideal microen-
vironment to study PC, because they lack a vascular
compartment and the environment is easily controlled
for confounding factors (e.g., see the fascinating work by
Gonzalez-Zulueta et al. [131]). In vitro modeling for
ischemia consists of oxygen and glucose deprivation
(OGD) in the culture medium, and perhaps the most
widely used method is the one described by Goldberg
and Choi [132,133]. This model includes the transfer of
neocortical cell cultures for several hours to an anaero-
bic chamber containing a gas mixture of 5% CO2, 10%
H2, and 85%N2 (oxygen deprivation), followed by appli-
cation of a deoxygenated glucose-free medium (glucose
deprivation). Organotypic hippocampal slice cultures
offer an attractive alternative method, because many
aspects of in vivo ischemia, such as delayed death of
CA1 neurons and selective vulnerability in response to
OGD, can be addressed [134]. Hassen et al. has intro-
duced a new model of IT by isolating hippocampal
slices from young rats, to abolish age-dependent resis-
t a n c et oi s c h e m i ci n j u r y[ 1 3 5 ] .A l s om i x e dn e o c o r t i c a l
cultures are available to study IT in vitro [136].
IV. Methods for detecting IT
In most of the IT studies, the ischemia-tolerant pheno-
type is addressed with assessments performed after the
final ischemia; however, to expose the molecular sub-
strates of latent cerebroprotective phenotype, the tissues
should be collected after PC (Figure 2). Studies, which
used the latter approach, have been recently reviewed
[137]. To increase the relevance to the human condition,
IT models should include both histological and func-
tional evaluations. However, these imply more challenges
for IT researchers [138], because not always a correlation
between these two outcome parameters is present [30].
Histological techniques
Determining the extent of injury after focal ischemia is
relatively simpler than after global ischemia. For this
purpose, traditional histological staining techniques,
such as hematoxylin-eosine and 2% solution of 2,3,5-tri-
phenyltetrazolium chloride, are often used. Digital cam-
era-based image analysis systems enable lesion area and
volume calculations. Ischemic lesion volume is calcu-
lated preferably with the correction of edema effect
[38,39,139,140]. In IT experiments, reduction in lesion
volume due to PC (lesion size in the näive brain –
lesion size in the preconditioned brain) can be calcu-
lated as a percent ratio to the lesion size in the näive
brain (Table 2). In global ischemia models, ischemic
damage is assessed in hippocampal sections stained with
toluidine blue [141], cresyl violet [34,94], or thionin
[142] by counting CA1 neurons, which are highly sus-
c e p t i b l et og l o b a li s c h e m i aa n de a s yt oq u a n t i f yd u et o
their laminar distribution and large size [138]. Protec-
tion due to PC can be reported as the percentage of
preserved healthy hippocampal CA1 neurons or number
of viable CA1 neurons [7,30,129]. In vitro models of IT
use cellular injury assessments, such as lactate dehydro-
genase assay [111,143].
Functional assessment
Gross measures of sensorimotor abilities are available for
rodents [37,144], and were introduced in IT experiments
[46,47,97,107]. However, in these species, gross sensorimo-
tor deficits tend to recover rapidly. That is, more complex
tests are needed, especially if outcome is assessed in long-
term. A number of somatosensory tests (e.g. limb placing,
beam walking, grid walking, rotarod) are available to apply
in focal ischemia rat models [145]. In global ischemia
models, tests of learning ability, and working and reference
memory are particularly useful [138,146].
Lesion evaluation by magnetic resonance imaging (MRI)
MRI technology allows for temporal and spatial moni-
toring of ischemic lesion and enables to conduct longi-
tudinal studies [147-151]. Besides requiring anesthesia,
MRI is risk-free for experimental animals. First MRI-
based lesion evaluation in an experimental IT study was
reported by Mullins et al. [152]. In a delayed IT model
(focal–focal ischemia), rats were imaged 24 and 72
hours after final ischemia. Interestingly, lesion reduction
due to PC was greater at 72 hours (70%) compared to
that at 24 hours (53%). Authors concluded that 24
hours post-ischemia, which is a common time-point for
lesion evaluation in experimental stroke studies
[153-155], may not be the best time-point for experi-
mental IT studies. Furuya et al., imaged rats serially (at
6 and 24 hours and 4, 7, and 14 days), following a
delayed IT paradigm (LPC-PC–focal ischemia) [156].
They evaluated whether decreased lesion size due to PC
would increase in long-term. No delayed lesion progres-
sion was found.
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Immmunohistochemistry is widely applied in IT
research and serves to evaluate tissue alterations by
means of antigen-antibody interactions. In situ hybridi-
zation and Western blotting techniques are applied to
examine the effect of PC on the investigated protein’s
mRNA expression and abundance [141]. DNA microar-
ray technology, which allows quantification and differen-
tial expression of thousands of genes simultaneously, has
been used to investigate global changes occurring
between ischemia-tolerant and näive brains (see below
“genomic reprogramming”). Real-time PCR can be used
for confirmation of the selected genes, which found
upregulated by microarray analysis [157]; proteomics
may provide supplemental insights [158]. Alterations in
neurotransmitter receptor density can be evaluated by
quantitative in vitro receptor autoradiography [159,160].
Autoradiographical methods may show changes in the
global protein status [29,161].
Showing attenuation or abolishment of IT by pharma-
cological inhibition of a molecule before or after PC sti-
m u l u sp r o v e sar o b u s ta p p r o a c h .W i t ht h i sa p p r o a c h ,
necessary or mandatory components of IT can be
explored [162,163]. Complementary information may
come from genetically modified animals by proving
abolishment of IT in mutants lacking a functional mole-
cule or protein and showing reestablishment of IT in
rescue experiments [164]. Maintenance of IT, despite
pharmacological inhibition of a molecule of interest or
despite the lack of this molecule in the mutant mouse,
may rule out the hypothetic causative role for the inves-
tigated molecule in the acquisition of IT [35,84,163].
However, it should be noted that, the main effectors of
IT can be model- or trigger-specific that, for instance, a
specific molecule proven mandatory for hypoxia-induced
IT in the rat brain [165] may not necessarily be required
in OGD-induced IT in vitro [166].
V. Mechanisms of IT
IT is achieved by the attenuation of broad categories of
injury-inducing mechanisms, including excitotoxicity,
ion and pH imbalance, oxidative and nitrosative stress,
metabolic dysfunction, inflammation, and apoptotic cell
death. Additionally, innate survival mechanisms and
enhanced endogenous repair mechanisms are involved
[5]. Preservation of energy metabolism and mitochon-
drial functions during the ischemic event is improved
[167,168]. Our knowledge on the underlying mechan-
isms of cerebral IT is yet patchy. Additionally, different
mechanisms may dominate different models. Here, we
will review only the major molecular aspects contribut-
ing to delayed cerebral IT. The mechanisms of early IT
will be discussed separately at the end of this section.
Readers seeking for more comprehensive information
should consult the recent excellent review of Obreno-
vitch [169] as well as its antecedents [9,133,167].
Hypoxia-inducible factor-1 (HIF-1)
Among several transcription factors sensitive to regula-
tion by hypoxia/ischemia, HIF isoforms have gained the
most experimental support [5]. HIF-1 proteins are
increased in the brain in the setting of hypoxia resis-
tance [170] and hypoxic PC [67]. Pharmacological acti-
vators of HIF-1 (deferoxamine or cobalt chloride)
promote PC in hypoxia/ischemia model in neonatal rats
[170]. Over the past decade, the signalling pathways
involved in HIF-1 activation have been deciphered in
detail [171]. Briefly, hypoxia stabilizes alfa subunit of
HIF-1, which enters the nucleus in a dimerized form
and results in the induction of HIF target genes. Several
HIF target genes contribute protection from ischemia
[67,172,173], and their products involve in wide range of
adaptive and pro-survival events, including cellular
metabolism, proliferation, vascularization, iron homeos-
tasis, and glucose metabolism [5,133].
Protein kinase C (PKC)
The role of protein kinase C in mediating stroke injury
has been reviewed recently [174]. There are 10 isozymes
in the PKC family. Previously, PKC was thought not to
h a v ear o l ei nI Tp h e n o m e n o n ,b e c a u s eb l o c k a g eo f
PKC did not prevent IT [175], and PKC activation did
not induce IT [176]. However, accumulating data sug-
gest opposite roles for different PKC isozymes in the
brain: gPKC contributes in ischemic cell death in orga-
notypic hippocampal cell cultures, and NMDA triggered
IT models require εPKC translocation [177]. Even
though non-selective activation of PKC does not induce
IT, specific εPKC activation leads to IT [143,177]. It
seems that adenosine-mediated activation of εPKC and
subsequent signal transduction pathways through
MAPK-K, ERK [178], and cyclooxygenase-2 induction
are involved in IT [143].
Anti-excitotoxic mechanisms, NMDA, and calcium
Exogenous application of NMDA or glutamate alone
s u f f i c et oi n d u c ei s c h e m i ar e s i s t a n c ei nc e l lc u l t u r e s ,
and NMDA receptor blockade during preconditioning
eliminates IT both in vitro [179] and in vivo [180,181].
Specific AMPA or kainate receptor blockade do not
eliminate or only partially attenuates IT [131,180]. Con-
tradictory findings exist, however [136,182]. In gerbils,
IPC increased inhibitory g-amino butyric acid A
(GABAA) receptor binding in hippocampus, whereas
final ischemia did not [160]. Moreover, microdialysis
experiments revealed a temporary increase in GABA
release in preconditioned rat hippocampus early after
final ischemia, with a decrease in glutamate
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induced in ischemia-tolerant state in global ischemia
models involve a shift between inhibitory and excitatory
hippocampal neurotransmission. In vitro, GABAB activa-
tion operates as a PC trigger [21], but not GABAA acti-
vation [21,183]. Regarding the role of Ca
2+ in IT, it
seems not always mandatory [184], but chelation of Ca
2
+ before and during both OGD- and NMDA-PC pre-
vents IT in vitro [177].
Adenosine and ATP-sensitive K
+ (KATP) channels
Adenosine, an ischemia-induced degradation product of
ATP, activates A1 receptors, which leads to a cascade of
signaling events including KATPchannels. This cascade
results in increased resistance to subsequent ischemic
damage [185]. The general role of KATP channels, which
are named for the inhibitory effect of ATP reducing chan-
nel opening probability, is to set membrane potential
according to its metabolic state by sensing intracellular
nucleotide concentrations [186]. Plasma membrane KATP
channels are found widely throughout the brain [186]. The
mandatory role of KATP channels for acquisition of IT was
demonstrated in a rat delayed IT model (global-global)
[187] and in vitro [188]. Interestingly, early IT is also
blocked by pharmacological inhibition of KATP channels in
vitro [176]. Opening of KATP channels is thought to relate
to adenosine A1 receptor activation. Both specific and
nonspecific adenosine A1 receptor antagonists attenuate
or cancel the IT phenomenon [187,189,190]. However,
SUR1-containing KATP channels seem not to be involved
in IPC [35] and in spreading depression-PC model in rats
and inhibition of KATP channels did not block IT [191].
Some authors emphasize a more pronounced role for
mitochondrial KATP channel in IT [169,190].
Nitric oxide (NO)
NO is one of the most extensively studied molecules in
IT experiments (for reviews see [192,193]). Data suggest
that generation of NO is crucial for the induction of IT,
as a dependence on endothelial NO synthase (eNOS),
but not on the neuronal NOS (nNOS) in newborn rats
subjected to hypoxic-PC [165]. Whereas, nNOS was
required to induce tolerance in vitro [166]. OGD toler-
ance in cortical cell cultures occurred via the activation
of the Ras/extracellular signal-regulated kinase cascade
by NO [131]. Atochin’s early IT model proved an indis-
pensable role for both eNOS and nNOS [50]. Puisieux
et al. used a delayed IT (focal-focal) model in adult rats
and showed no effect of NOS blockade on IT, but when
the PC stimulus was LPS, ITw a sa b o l i s h e db yN O S
inhibition [194]. Inducible NOS (iNOS) lacking mice
experience no IT [164] and iNOS inhibition may nullify
delayed IT to permanent focal ischemia, that otherwise
follows isoflurane- or halotane-PC [113].
Anti-inflammatory mechanisms
Interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-
a) are implicated in IT induction: both cytokines are
found increased in ischemic-tolerant state, both act as
PC trigger when administered systemically, and their
inhibition or lack significantly attenuate or block IT
[195-198]. Pradillo et. al. explored the involvement of
the TNF-a/nuclear factor-B( N F - B) signal transduc-
tion pathway in IT [48]. This pathway includes at least
131 interactors [199]. Activation of NF-B is involved in
IT in several models [200,201], likely via the induction
of neuroprotective gene products, such as manganese
superoxide dismutase and Bcl-2 [9]. Preconditioning
with ligands of toll-like receptors 4 and 9 may alter
innate inflammatory responses to ischemia by causing
an initial activation of inflammatory mediators followed
by a burst of inflammation inhibitors [202].
Anti-apoptotic mechanisms
PC blocks enhanced phosphorylation occurring after
ischemia [9]. On the other hand, phosphorylation of
transcriptional factors can induce long-term changes by
regulating the expression of genes. IT is also character-
ized by reduced apoptosis [5,142]. Phosphaphatidylinosi-
tol 3-kinase/Akt pathway seems to act in two ways: 1)
in relation to anti-apoptotic mechanisms and 2) by acti-
vating NFkB. In vitro, p21 Ras is required and sufficient
to induce IT and Ras/Erk pathway is activated through
NMDA receptor and NO production [131]. However,
increasing evidences support the existence of a link
between Akt activation anda n t i - a p o p t o s i si nI T
[157,203-205], perhaps more persistently in penumbral
regions in focal IT models [206]. Anti-apoptotic
mechanisms induced by PC are several: induction of
Bcl-2, reductions in caspase-3 synthesis and p-53 activa-
tion, and reductions in mitochondrial cytochrome c
[9,185].
Genomic reprogramming
With the contribution of DNA microarray analysis
method to IT research, we gained a better understand-
ing of the preconditioned brain on the genetic level. In
2003, Stenzel-Poore and colleagues published a study, a
cornerstone in the field, which introduced the concept
of “genomic reprogramming” defining the altered tran-
scriptional response of the ischemia-tolerant brain [207].
Followed by others [208,209], profiled the genetics of IT
induced by IPC in rats were profiled. In the setting of
IT, overall transcriptional response to injury was found
altered as downregulation, which was strikingly different
from that in the naïve brain’s postischemic transcrip-
tome. Suppression of gene expression in the ischemia-
tolerant state was not simply the lack of response to
injurious insult, but rather a reprogramming of the
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suppressed are involved in the pathways that regulate
metabolism, molecular transport, or cell-cycle control.
Genomic transcriptional profile shows a substantial dif-
ference also between latent cerebroprotective and ische-
mia-tolerant states. None but one of the differentially
regulated genes compared to healthy hemisphere are in
common [208]; however, in both states, overall response
is downregulation of genes involved in metabolism and
transport/synaptic transmission. Using GeneChip analy-
sis, Dhodda et al. evaluated temporal changes in gene
expression after IPC in spontaneously hypertensive rats
[158]. At the time-points studied (3, 6, 12, 24, and 72 h
after PC), overall 40 transcripts were found up-regu-
lated, among which 30 transcripts were overexpressed at
all time-points, and the six HSP70 transcripts showed
the highest increase. Other major families of transcripts,
which were upregulated during PC, were those that con-
trol signal transduction, transcription, ionic homeostasis,
and plasticity. Moreover, transcripts that showed upre-
gulation after ischemia in näive brains were not found
upregulated in ischemia-tolerant brains [158].
Gene expression response to hypoxic-PC was also stu-
died [173]. As early as 1 hour after hypoxia, but at a
g r e a t e re x t e n ta t6h o u r s ,e x p r e s s i o no fm a n yg e n e s ,
which are regulated by HIF-1, were increased. Com-
pared to näive ischemic brains, in the ischemia-tolerant
brains preconditioned with hypoxia, several genes were
differentially upregulated. Genes with decreased expres-
s i o ni nn ä i v ei s c h e m i cb r a i n sw e r en ol o n g e ro ro n l yt o
a small degree underexpressed in ischemia-tolerant
brains.
Genetic response to hyperbaric oxygen-PC was studied
in the rat, in the latent cerebroprotective state (at 6, 12,
24 after PC) [71]. Most of the differential regulations,
including overexpression of genes and proteins related
to neurotrophin and inflammatory-immune system,
occurred around 12 and 24 hours. Genetic reprogram-
ming was described as well for IT induced by erythro-
mycin [118].
Mechanisms of early IT
In vivo models demonstrating early IT in the brain are
limited: global-global model in the rat [24], and focal-
focal model both in the rat [211], and mouse [49,50],
and anesthetic-PC against focal permanent ischemia in
the rat [113].
The molecular mediators of early IT are little known.
Changes in membrane channel activity and posttransla-
tional modifications of existing proteins are among the
few, which are well-described. Roles for adenosine
receptor in vivo [211] and for KATP channel in vitro
were also explored [176]. Several immediate-early genes
(c-fos, c-jun), growth factors (brain-derived neurotrophic
factor, nerve growth factor), and heat shock protein 70
were overexpressed during early latent ischemia-tolerant
state [212]. According to Kariko et al. [213], during
early tolerance, production of proinflammatory cyto-
kines are suppressed, whereas in delayed tolerance, pro-
duction of the very same cytokines are induced.
VI. Open Issues and Challenging Features of IT
Several specific questions arise by an overview of past IT
experiments. The nature of the PC stimulus and the
duration of the interval between PC and final ischemia
are among the main parameters that may affect the
results. The strain and gender of the experimental ani-
mal are additional sources of variability, as we are famil-
iar from stroke experiments. Therefore, findings of an
experimental IT study should be interpreted considering
the following issues.
Trigger-dependent differences
Experimental data amounted for the last 20 years clearly
demonstrated that IT can be afforded in animals by mis-
cellaneous PC triggers. Thus, one can both easily and
reasonably make the following assumption: diverse PC
are sharing a common or overlapping pathway. As dis-
cussed above, a number of effector mechanisms confer
ischemia-tolerant phenotype, and recently, genetic
reprogramming was proposed as the underlying com-
mon process set into motion by these mechanisms
[207,208]. Below, we will have a closer look to studies
comparing the mechanistic or molecular features of IT
triggered by different PC stimuli.
IPC versus LPS-PC was compared in a transient ische-
mia rat model and found inducing similar degree of pro-
t e c t i o n( 3 5 %r e d u c t i o ni ni n f a r c tv o l u m e )[ 1 9 4 ] .A n
interesting finding was that NO synthase inhibition
abolished the protective effect of LPS, but not of IPC.
IPC induced the expression of heat shock protein 70 in
the cerebral cortex, but LPS did not. Recently, ischemia-
tolerant phenotypes induced by two well-known precon-
ditioning stimuli -LPS and transient focal ischemia-
have been evaluated from the genetic aspect [209].
Authors disclosed that a substantial subset of regulated
genes were unique to each PC stimulus. In case of IPC,
mainly metabolism and channel/transport-related genes
were suppressed; whereas, LPS-PC induced expression
of pro-inflammatory molecules and suppressed those
genes related to deleterious inflammatory reactions.
However, suppression of Toll-like receptor-mediated
inflammation is a common mechanism triggered by
both PC triggers [213]. Another comparative study of
different PC stimuli (IPC and chemical PC with 3-NPA)
addressed cytokine mRNA expression after final ische-
mia [214]. Both PC strategies exerted very similar effects
on proinflammatory and cytotoxic cytokine expressions.
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growth factor separately with IPC and 3-NPA-PC para-
digms [215]. Neither trigger showed any effect on nerve
growth factor expression, which in another study was
found increased by PC with brief global ischemia in
both early and delayed IT [212].
Intermodel differences
In focal-global IT paradigm, PC may confer IT in neu-
rons outside the primary area subjected to IPC that is in
proximity, but not in the further regions such as con-
tralateral hippocampus [62]. Similar IT paradigm in rats
resulted in bilateral protection of hippocampi, however
[63]. A functional direct pathway from the entorhinal
cortex to both hippocampi was suggested to reflect the
changes afforded by IPC to both hemispheres [63]. In
the global-global IT paradigm, c-fos expression during
the tolerant state was found specific to the cell type
[216], which may explain selectivity of IT induction to
certain brain areas.
Prass et al. studied the confounding effects of strain
and reperfusion on the IT phenomenon [69]. Hyperbaric
oxygen was applied as PC stimulus to two common
background strains for knockout mice, SV129 and
C57BL/6. Final ischemia was either permanent or transi-
ent focal ischemia. In SV129 mice, PC induced tolerance
to permanent ischemia but not to transient ischemia. In
C57BL/6 mice, IT did not occur at all. Consequently,
questions to answer with further study are: 1. For what
reasons the very same trigger induced IT in a strain but
not in another, and 2) Can reperfusion nullify the pro-
tection afforded by PC?
Gender
Female rats sustain smaller infarcts after MCAO than
males [217] and estrogen is neuroprotective in ovariecto-
mized females and in males subjected to ischemic stroke
[218]. Data from heart IT experiments show a clear gen-
der-dependency of the IT phenomenon [219,220], this
issue seems valid also in cerebral IT. Estrogen provided
IT in a model of hippocampal organotypic slice culture,
which was generated from neonatal female rats [116],
and isoflurane induced IT only in male mice and
increased the infarction in young female mice [221].
Age
IT phenomenon is preserved in aged animals [222], but
may not be as effective as it is in young animals. This
aspect was tested with a global-global IT paradigm
applied in 4- and 24-month-old rats [223]. The degree
of protection due to PC was significantly diminished in
aged rats compared to young rats. A retrospective clini-
cal study indicated that IT may not be occurring in the
elderly, aged around 75 [224].
Repeated PC
Cumulative injurious effect of repeated cerebral ische-
mia is a well-known phenomenon. For example, three
periods of 5-min forebrain ischemia, induced at 1-hour
intervals, result in more extensive brain injury than one
single episode of 15-min ischemia in gerbils [225]. How-
ever, if PC insults are applied repeatedly, a larger IT
response may be gained. This was tested in a mice
model of early IT, in which animals underwent either
single or 3 episodes of 5-min focal cerebral ischemia, 30
min before permanent ischemia [49]. Only repeated
insults conferred IT, the single brief ischemia was insuf-
ficient to induce IT. Similarly, a single episode of 2 min
OGD is under the threshold to act as a PC stimulus,
but four times repeated 2 min of OGD show a cumula-
tive effect and protects from subsequent injurious insult
[226]. Hyperbaric oxygen-PC, when applied singly or
repeatedly, provide similar degree of protection from
transient focal ischemia (63% vs 73% lesion reduction)
[227], perhaps this is the maximum affordable protec-
tion by hyperbaric oxygen. In a clinical study however,
anesthetic-PC with a single application induced no IT in
the heart, whereas repeated application did [115]. In the
p i gh e a r t ,P Cb yr e p e t i t i v ei s c h e m i ci n s u l t sw a ss h o w n
to induce a different set of genetic regulations from
those induced with PC with single ischemic episode
[228]. A corresponding study in cerebral IT is needed.
“Sublethality” of PC
Although PC is defined as a sublethal stimulus, which
per se causes no injury, several studies used relatively
severe focal ischemia as the PC trigger and were able to
induce IT, despite the injurious nature of the PC itself
[63,64,190]. As pointed out by Sommer [137], with
extended follow-up after the PC insult, some injury or
structural changes can be detected. Therefore, it is sug-
gested that PC is postponing these changes [137]. If that
holds true, in the long-term, näive ischemic brains and
IT experienced brains may have similar outcomes. This
issue is discussed next.
IT and long-term effects
Early IT is a short-lasting phenomenon, its protection
vanishes around 7 days [24]. In delayed IT models, pro-
tection lasts longer and tends to decline after 30-60
days. Ohno et al. applied a global-global IT model to
rats [229] and showed that improvement in learning and
memory due to IPC was preserved up to 3 weeks. Pro-
tective effects of spreading depression-PC and LPS-PC
sustained up to 14 days [84,156]. Ma et al. found a sus-
tained improvement in neurological scores up to 30
days in xenon-preconditioned neonatal mice subjected
to global ischemia [112], a similar finding was reported
with a focal-focal IT model in rats [51]. In global-global
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rats (up to 90 days) than in gerbils (up to 60 days)
[30,32,222,230]. Optimizing time interval between PC
and final ischemia, together with the optimization of the
PC stimulus (single or repetitive application) and the
severity of final ischemic insult, may result in long-term
preservation of protection achieved by PC [32], on
which increased neurogenesis after PC [231] may have a
potential role.
VII. Clinical Aspects
To date, a body of evidence, which supports the hypoth-
esis that TIAs may confer IT in humans, exists. In a ret-
rospective study, preceding TIA was found to be
associated with less-severe stroke on admission and
improved outcome on follow-up, compared to stroke
patients without preceding TIA [232]. Another retro-
spective case-control study, found no evidence of PC by
TIA in baseline neurological scores, but favorable out-
come was associated with the presence of TIA [233].
This study presented “potentially preconditioning” TIA
characteristics as: 0-7 day interval between TIA and
stroke, 2 or 3 times repeated TIA, and TIA with <20
min duration. Moncayo et al. reported a cohort of 65
patients with acute anterior circulation stroke, among
whom those with previous TIAs (lasting less than 20
minutes), had a more favorable outcome than those
without [234]. Apparently, duration of TIA should be
taken into account while evaluating whether IT exists in
humans or not [235]. An MRI study provided the tissue
evidence for TIA-induced tolerance to ischemic stroke
[236]. Ischemic lesions tended to be smaller on the
baseline images and final infarct volumes were smaller
in stroke patients with prior TIA than in those without.
Although these findings strongly suggest TIA as the
clinical correlate of IPC, other explanations for milder
strokes after preceding TIA must be considered. In
these patients, a carotid disease with slowly progressing
stenosis, which improves collateral circulation may pre-
dominate [237]. Another point is that, patients with car-
dioembolic stoke have lower incidence of TIA than
those with atherosclerotic vascular disease, and probably
because of larger-sized emboli they sustain larger
infarcts and poorer outcome [238].
Several clinical conditions may benefit from strategies
using principles of ischemic tolerance, as discussed ele-
gantly by Dirnagl et al. in a recent review article on cer-
ebral IT [239]. Mediators of IT could be used as
biochemical markers of IT in stroke patients. Castillo et
al. tested this hypothesis by evaluating blood levels of
TNF-a and IL-6 in acute stroke patients with or without
prior ipsilateral TIA [240]. Better outcome was found in
patients with TIA, who showed high plasma concentra-
tions of TNF-a and low concentrations of IL-6. Hence,
authors proposed the index of TNF-a/IL-6 as a marker
of IT phenomenon in humans.
Conclusions
Experimental IT paradigms investigate the endogenous
pathways by which the brain might protect itself from
ischemia when geared with an appropriate stimulus.
Attempts to elucidate the mechanisms underlying cere-
bral IT are increasing exponentially, but diversity of
models, including PC stimuli, hardens interpretation of
the data. In addition, narrow safety margin of PC may
prove a limiting factor of the therapeutic utility of PC in
clinics. On the other hand, accumulating clinical data
suggest that IT might be a clinically relevant phenom-
enon. Several approaches, including ICP [241], remote-
PC by limb ischemia [88], pharmacological-PC with
nitroglycerine [242], and anesthetic-PC [115], are tested
in clinical trials to protect the heart from cardiovascular
interventions with high risk of cardiac ischemic event.
Results are promising and give hope that clinical trials
of PC to protect brain in situations with a high risk of
ischemia can be designed, once PC is proven safe.
Additional file 1: Models for ischemic tolerance in rodents.
Click here for file
[http://www.biomedcentral.com/content/supplementary/2040-7378-2-2-
S1.XLS]
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